*Cryptosporidium* species is a major pathogen causing moderate to severe diarrhea in children \[[@CIT0001], [@CIT0002]\]. In India alone, cryptosporidiosis causes 3.9--7.1 million diarrheal episodes, 66 400--249 000 hospitalizations, and 5800--14 600 deaths in children aged \<2 years \[[@CIT0003]\]. Cryptosporidiosis is associated with long-term sequelae, with significant adverse effects on nutritional status, cognitive development, increased diarrheal burden, and mortality in children \[[@CIT0004], [@CIT0005]\].

Although studies show high cryptosporidial disease burden in developing countries \[[@CIT0003], [@CIT0005]\], the epidemiology of human cryptosporidiosis is not clearly understood. There is a dearth of longitudinal data on the course of infection in the absence of overt diarrheal disease. An understanding of the natural history of cryptosporidiosis and correlates of protection are essential in developing effective disease control and preventive measures. We conducted intensive active surveillance of children from birth till 3 years of age in a semiurban area in southern India by harnessing the synergistic benefits of a birth cohort design in a community setting and efficient molecular approaches to detect cryptosporidial infections.

MATERIALS AND METHODS {#s1}
=====================

Site Recruitment, Follow-up, and Definitions {#s2}
--------------------------------------------

A birth cohort of 497 newborns was recruited between March 2009 and May 2010 in periurban Vellore, Tamil Nadu, India. In this population, human immunodeficiency virus (HIV) prevalence in antenatal women is \<0.3% and there is an effective prevention of transmission program; hence, we did not screen for HIV. Children with very low birth weight (\<1500 g) or congenital malformations were excluded. Enrollment, twice-weekly follow-up, and a description of illness in the cohort have been published \[[@CIT0006]\]. Surveillance stool samples were collected every 2 weeks. For diarrhea, 3 stool samples were collected on separate days from day 1 to day 7 from the start of the episode. Severity of diarrheal episodes was assessed using the Vesikari scoring system \[[@CIT0007]\]. Cord blood, where possible, or peripheral blood within 45 days after birth was collected from the infant. Every 6 months, 3- to 5-mL blood samples were collected from the study children.

Diarrhea was defined as ≥3 loose, watery stools in a 24-hour period \[[@CIT0008]\], with an episode defined as at least 1 day of diarrhea, preceded and followed by at least 2 days without diarrhea. Cryptosporidiosis/cryptosporidial infection was identified by polymerase chain reaction (PCR) detection of *Cryptosporidium* species in stool or a 4-fold increase in immunoglobulin G (IgG) levels to gp15 and/or Cp23 between 2 serum samples. A diarrheal episode was termed symptomatic cryptosporidiosis if a stool sample collected within ±7 days was PCR positive. Cryptosporidiosis identified by stool PCR was asymptomatic if the stool was PCR positive but there was no diarrhea ±14 days. A new asymptomatic episode was considered when there was at least a 2-week gap with an intervening stool sample negative for *Cryptosporidium* species. Asymptomatic cryptosporidiosis identified by serology was a 4-fold increase in IgG to gp15 and/or Cp23 between 2 sera with no diarrhea or stool PCR positivity during that period. When a child was positive for asymptomatic infection by both stool PCR and serology during a defined interval, only stool PCR was considered and the child was not double-counted. Symptomatically undifferentiated cryptosporidiosis occurred when there was a 4-fold increase in IgG levels between 2 sera with a history of diarrhea during the period, but all stools were PCR negative. Cryptosporidial infection includes asymptomatic and symptomatic infections, while disease refers to symptomatic infection.

Testing for *Cryptosporidium* in Stool {#s3}
--------------------------------------

DNA extracted from stool using a QIAamp DNA stool mini kit (Qiagen, Valencia, California) was screened by conventional 18S ribosomal RNA (rRNA) nested PCR for *Cryptosporidium* species using published protocols \[[@CIT0009], [@CIT0010]\]. Appropriate negative (no DNA template) and positive (known *C. hominis* or *C. parvum* PCR-positive stool) controls were included in every extraction and PCR run. For PCR-positive samples, species was determined by restriction fragment-length polymorphism and confirmed by 18S rRNA amplicon sequencing \[[@CIT0011]\].

Identification of Enteric Pathogens in Diarrhea {#s4}
-----------------------------------------------

Other than testing for *Cryptosporidium* species, which was by PCR, all diarrheal stool samples were tested for the presence of bacterial, viral, and parasitic pathogens using the Interactions of Malnutrition and Enteric Infections (MAL-ED) study protocols \[[@CIT0012]\], which tested for multiple bacterial, viral, and parasitic pathogens.

ELISA for IgG to Gp15 and Cp23 in Serum {#s5}
---------------------------------------

Serum IgG was measured by enzyme-linked immunosorbent assay (ELISA) using recombinant gp15 and Cp23 \[[@CIT0013]\] as antigens, with results expressed as arbitrary ELISA units. Samples with positive ELISA unit values were considered seropositive.

MHC Class II Typing {#s6}
-------------------

Major histocompatibility complex (MHC) class II typing was performed in a subset of 74 children, of whom 41 had only asymptomatic infection and 33 had ≥2 infections with at least 1 symptomatic infection. We chose children from whom sufficient genomic DNA was available, so a power calculation was not performed to determine the ideal sample size. There is no information of human leukocyte antigen (HLA) alleles in this population, which consists of a mix of religions and ethnic backgrounds in southern India. DNA was extracted from blood using a DNeasy Blood and Tissue kit (Qiagen). HLA class II (DR and DQ) alleles expressed by the MHC genes were identified by PCR with sequence-specific oligonucleotide probes using a Luminex-based method with a Rapid Lifecodes kit (Tepnel Lifecodes Corporation, Stamford, Connecticut).

Statistical Analysis {#s7}
--------------------

Data were analyzed using Stata software, version 12.1 for Windows (StataCorp, College Station, Texas) and R version 2.12.1 (<http://www.r-project.org/>), with analyses confined to the 410 children who completed 3 years of follow-up. The baseline demographic characteristics of 87 children who did not complete the study did not differ significantly from those included in the analysis ([Supplementary Table 1](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw730/-/DC1)). Comparisons used the χ^2^ or Fisher exact test for categorical variables and 2-tailed *t* test or Wilcoxon rank-sum test for continuous variables. The cumulative incidence of cryptosporidial infections was calculated using survival analysis, adjusted for the duration of follow-up of each child and expressed as number of episodes per child-year. Based on the assumption that cryptosporidiosis would follow a Poisson distribution, the number of children expected to have 0, 1, 2, 3, 4, 5, and 6 episodes of cryptosporidiosis was calculated and compared with the observed frequency to verify if there was clustering of cryptosporidiosis in children.

For protective effects of prior cryptosporidial infection, parametric Poisson regression survival models were used to obtain relative risks and confidence intervals adjusted for repeated infection in the same child. The adjusted relative risks and protective efficacy of prior cryptosporidial infections were adjusted for factors previously reported to be associated either with overall morbidity \[[@CIT0006]\] or cryptosporidiosis \[[@CIT0016]\].

The role of antibody-mediated protection was studied using the effect of presence of serum IgG to gp15 and Cp23 on subsequent infection rates. When there were multiple cryptosporidial infections between 2 sera, analysis was restricted to the first episode. Parametric Poisson regression survival models were used to model the risk of cryptosporidial infection or disease as a function of preexisting antibody levels. Serum IgG levels to gp15 and Cp23 were categorized into quartiles to examine a dose--response relationship between antibody levels and protection. The IgG level was included as a categorical variable with absence of antibody as the reference category. The model was adjusted for age and number of previous infections.

Allele frequencies were counted for analysis of HLA data, with an allele frequency of \>10% used for genetic association analysis. The association between HLA markers and occurrence of symptomatic and asymptomatic cryptosporidial infection was measured by calculating the odds ratio, using logistic regression.

Ethics Approval
---------------

Written informed consent was obtained from the parents or guardians of children in the study. The study was approved by the institutional review boards of the Christian Medical College, Vellore, India, and the Tufts University Health Sciences campus, Boston, Massachusetts.

RESULTS {#s8}
=======

Burden of Cryptosporidiosis {#s9}
---------------------------

Of 497 recruited children, 410 completed 3 years of follow-up contributing 1218 child-years. The most common reason for children not completing the study was permanent migration out of the study area. Of the 410, 397 (97%) had cryptosporidiosis; 237 (59.7%) had only asymptomatic infections and 119 (30%) developed both symptomatic and asymptomatic cryptosporidial infections ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). Among the remaining children, 24 (6.0%) children had 1 or more episodes of symptomatic infection but no asymptomatic infection and 17 (4.3%) children had undifferentiated cryptosporidial infection detected only by serology. There was no difference by sex for asymptomatic (*P* = .10) or symptomatic infections (*P* = .17).

![Number of children in a birth cohort in Vellore, India, who completed 3 years of follow-up (n = 410) who had cryptosporidiosis detected by polymerase chain reaction (PCR) or serology.](clinid_ciw730_f0001){#F1}

![Number of symptomatic and asymptomatic cryptosporidial infections detected in a birth cohort in Vellore, India, who completed 3 years of follow-up. Abbreviation: PCR, polymerase chain reaction.](clinid_ciw730_f0002){#F2}

Infection occurred by 6 months of age in 165 (40.2%) children, by 2 years in 379 (92.4%), and by 3 years in 397 (97%). Symptomatic cryptosporidiosis was seen in 24 (5.8%), 55 (13.4%), 116 (28.3%), and 143 (35%) children by 6 months and 1, 2, and 3 years of age, respectively. The median age at first cryptosporidial infection was 9 (interquartile range \[IQR\], 4--17) months, with no difference (*P* = .75) between asymptomatic (8 \[IQR, 4--14\]) and symptomatic (9 \[IQR, 3--16\]) infection ([Supplementary Figure 1](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw730/-/DC1)). Overall, the incidence of cryptosporidiosis was 0.86 episodes (symptomatic 0.16, asymptomatic 0.57) per child-year, with the highest incidence (1.01 episodes per child-year) in the first year of life ([Table 1](#T1){ref-type="table"}).

###### 

Age Distribution and Incidence of Cryptosporidiosis in a Birth Cohort (n = 410) in Vellore, India, Followed up to 3 Years of Age

  Cryptosporidial Infection                    0--1 y             \>1--2 y          \>2--3 y          0--3 years
  -------------------------------------------- ------------------ ----------------- ----------------- -----------------
  Child years of follow-up                     403.5              406.09            408.55            1218.1
  Overall infection                                                                                   
   Episodes                                    406                358               289               1053
   Incidence rate                              1.01 (.93--1.08)   0.88 (.81--.96)   0.71 (.64--.78)   0.86 (.82--.90)
  Symptomatic infection                                                                               
   Episodes                                    66                 86                47                199
   Incidence rate                              0.16 (.12--.21)    0.21 (.17--.27)   0.11 (.09--.15)   0.16 (.14--.19)
  Asymptomatic infection                                                                              
   Episodes                                    223                246               224               693
   Incidence rate                              0.55 (.49--.62)    0.60 (.55--.67)   0.55 (.49--.62)   0.57 (.53--.61)
  Symptomatically undifferentiated infection                                                          
   Episodes                                    117                26                18                161
   Incidence rate                              0.29 (.25--.34)    0.06 (.04--.09)   0.04 (.03--.07)   0.13 (.11--.15)

Incidence rates are shown as incidence rate (95% confidence interval) per child-year.

Clustering of Cryptosporidial Infection {#s10}
---------------------------------------

Among 410 children, 63 (15.4%) had only 1 infection, 132 (32.2%) had 2, 113 (27.6%) had 3, 64 (15.6%) had 4, and 25 (6.1%) had ≥5 infections. There was clustering of infection (χ^2^ test for goodness of fit = 1755.21; degrees of freedom = 6; *P* \< .0001). Similarly, among 143 children with symptomatic infection, 99 (69.2%) had only 1 episode, 36 (25.2%) had 2 episodes, and 8 (5.6%) had ≥3 episodes of symptomatic cryptosporidiosis, with evidence of clustering (χ^2^ test for goodness of fit = 25.04; degrees of freedom = 5; *P* \< .0001).

Clinical Features of Symptomatic Cryptosporidiosis {#s11}
--------------------------------------------------

Of 2134 diarrheal episodes, at least 1 stool sample was obtained for 2121 (99.4%) episodes, and 199 (9.4%) were *Cryptosporidium* positive by PCR. Most (197 \[99%\]) were acute diarrhea (≤14 days' duration), with a median duration of 3 (IQR, 2--4) days, similar to that of noncryptosporidial diarrhea ([Table 2](#T2){ref-type="table"}). Of the 199 symptomatic cryptosporidial episodes, clinical features and severity did not differ from noncryptosporidial diarrhea ([Table 2](#T2){ref-type="table"}). There were 48 (24%) episodes of symptomatic cryptosporidiosis where co-pathogens, predominantl*y Giardia* (27 \[13%\]) and *Shigella* (12 \[6%\]), were found.

###### 

Clinical Characteristics of Diarrheal Episodes in Which *Cryptosporidium* Species Was Identified by Polymerase Chain Reaction and Other Episodes in a Birth Cohort in Vellore, India, Followed up to 3 Years of Age

  ---------------------------------------------------------------------------------------------------------------------------------
  Clinical Characteristics                     Symptomatic Cryptosporidiosis (n = 199)   Noncryptosporidial Diarrhea\   *P* Value
                                                                                         (n = 1922)                     
  -------------------------------------------- ----------------------------------------- ------------------------------ -----------
  Median (IQR) age, mo                         16 (9--24)                                10 (6--20)                     \<.0001

  Median (IQR) duration, d                     3 (2--4)                                  3 (2--4)                       --

  Accompanying symptoms, No. (%)                                                                                        

   Vomiting                                    45 (22.6)                                 455 (23.6)                     .86

   Fever                                       40 (20.1)                                 450 (23.4)                     .29

  Treatment required, No. (%)                                                                                           

   Clinic visits                               117 (58.8)                                1235 (64.3)                    .12

   Hospitalization                             7 (3.5)                                   47 (2.4)                       .36

   Intravenous fluids                          1 (0.5)                                   13 (0.7)                       .77

  Severity of diarrheal episodes^a^, No. (%)                                                                            

   Mild                                        95 (47.7)                                 955 (49.8)                     .76

   Moderate                                    80 (40.2)                                 758 (39.5)                     

   Severe                                      24 (12.0)                                 203 (10.6)                     
  ---------------------------------------------------------------------------------------------------------------------------------

Abbreviation: IQR, interquartile range.

^a^Data not available for 6 episodes.

Protection Conferred by Natural Infection {#s12}
-----------------------------------------

The incidence of cryptosporidial infection, but not disease, decreased as the number of infections increased ([Table 3](#T3){ref-type="table"}). The adjusted efficacy after 4 prior infections was 69% against infection, 70% against asymptomatic infection, and 66% against undifferentiated cryptosporidial infection, although the efficacy against symptomatic infection was lower and insignificant (19%). To explore the reason for the lower protection against symptomatic infection, a subgroup analysis was performed excluding 8 children who had \>2 symptomatic infections. It showed improved protective efficacy against symptomatic infection, indicating that certain children pushed the protective effect toward the null ([Supplementary Table 2](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw730/-/DC1)).

###### 

Protective Effect of Prior Cryptosporidial Infection on Subsequent Infection or Disease Graded by the Number of Previous Infections in Birth Cohort (n = 410) Followed up to 3 Years of Age in Vellore, India

  Exposure as No. of Previous Cryptosporidial Infections            Person-years of Follow-up   No. of Infections   Incidence Rate per Child-year (95% CI)   Relative Risk of Subsequent Event (95% CI)   Adjusted Protective Efficacy, % (Range)                      
  ----------------------------------------------------------------- --------------------------- ------------------- ---------------------------------------- -------------------------------------------- ----------------------------------------- ------------------ ------------------
  Any cryptosporidial infection                                                                                                                                                                                                                                        
   0                                                                336.68                      397                 1.18 (1.07--1.29)                        1                                            1                                         1                  1
   1                                                                382.77                      334                 0.87 (.79--.95)                          0.74 (.65--.83)                              0.71 (.61--.82)                           0.69 (.60--.80)    31 (20--40)
   2                                                                284.89                      202                 0.71 (.63--.80)                          0.60 (.52--.69)                              0.56 (.46--.68)                           0.53 (.44--.65)    47 (35--56)
   3                                                                142.34                      89                  0.62 (.51--.76)                          0.53 (.43--.65)                              0.50 (.38--.65)                           0.45 (.35--.60)    55 (40--65)
   4                                                                71.46                       31                  0.43 (.31--.63)                          0.37 (.26--.52)                              0.35 (.23--.52)                           0.31 (.20--.46)    69 (54--80)
  Asymptomatic infection                                                                                                                                                                                                                                               
   0                                                                336.68                      229                 0.68 (.60--.77)                          1                                            1                                         1                  1
   1                                                                382.77                      238                 0.62 (.56--.69)                          0.91 (.78--1.06)                             0.78 (.65--.94)                           0.76 (.63--.91)    24 (9--37)
   2                                                                284.89                      144                 0.50 (.43--.59)                          0.74 (.61--.90)                              0.57 (.45--.73)                           0.54 (.43--.69)    46 (31--57)
   3                                                                142.34                      59                  0.41 (.33--.53)                          0.61 (.46--.80)                              0.45 (.32--.62)                           0.41 (.30--.57)    59 (43--71)
   4                                                                71.46                       23                  0.32 (.21--.52)                          0.47 (.30--.74)                              0.34 (.21--.56)                           0.30 (.18--.51)    70 (49--82)
  Symptomatic infection                                                                                                                                                                                                                                                
   0                                                                336.68                      64                  0.19 (.15--.24)                          1                                            1                                         1                  1
   1                                                                382.77                      60                  0.16 (.12--.20)                          0.82 (.60--1.12)                             0.78 (.54--1.13)                          0.75 (.52--1.09)   25 (--9 to 48)
   2                                                                284.89                      44                  0.15 (.12--.21)                          0.81 (.55--1.19)                             0.81 (.52--1.29)                          0.75 (.47--1.20)   25 (--20 to 53)
   3                                                                142.34                      23                  0.16 (.10--.24)                          0.85 (.53--1.35)                             0.96 (.54--1.69)                          0.86 (.47--1.55)   14 (--55 to 53)
   4                                                                71.46                       8                   0.11 (.05--.27)                          0.59 (.27--1.25)                             0.72 (.30--1.71)                          0.63 (.27--1.48)   37 (--48 to 73)
  Moderate to severe symptomatic infection (Vesikari score 6--20)                                                                                                                                                                                                      
   0                                                                336.68                      42                  0.12 (.09--.17)                          1                                            1                                         1                  1
   1                                                                382.77                      31                  0.08 (.05--.12)                          0.65 (.43--.97)                              0.66 (.40--1.07)                          0.62 (.38--1.02)   38 (--2 to 62)
   2                                                                284.89                      16                  0.06 (.03--.09)                          0.45 (.26--.79)                              0.53 (.27--1.01)                          0.47 (.24--.91)    45 (9--76)
   3                                                                142.34                      10                  0.07 (.04--.14)                          0.56 (.29--1.09)                             0.83 (.37--1.88)                          0.71 (.30--1.68)   29 (--68 to 70)
   4                                                                71.46                       5                   0.07 (.03--.20)                          0.56 (.24--1.29)                             0.98 (.34--2.83)                          0.81 (.28--2.28)   19 (--128 to 72)
  Symptomatically undifferentiated infection                                                                                                                                                                                                                           
   0                                                                336.68                      104                 0.31 (.25--.38)                          1                                            1                                         1                  1
   1                                                                382.77                      36                  0.09 (.07--.13)                          0.30 (.21--.44)                              0.45 (.31--.65)                           0.44 (.30--.63)    56 (37--70)
   2                                                                284.89                      14                  0.05 (.03--.09)                          0.16 (.09--.28)                              0.33 (.19--.59)                           0.31 (.18--.56)    69 (44--82)
   3                                                                142.34                      7                   0.05 (.02--.12)                          0.16 (.07--.34)                              0.37 (.16--.83)                           0.34 (.15--.77)    66 (23--85)
   4                                                                71.46                       0                   --                                       --                                           --                                        --                 --

Abbreviation: CI, confidence interval.

^a^Adjusted for age, sex, presence of sibling, maternal age \<23 years, use of firewood for cooking.

In children with multiple infections, the severity of diarrhea did not significantly decrease between the first and second infections (*P* = .93) or between the second and third infections (*P* = .32). Similarly, in children with multiple symptomatic infections, the severity of diarrhea between the first and second (*P* = .19) or between the second and third (*P* = .39) episodes did not significantly decrease.

Association of Serum Antibodies With Protection Against Cryptosporidial Infections and Diarrheal Disease {#s13}
--------------------------------------------------------------------------------------------------------

Serum gp15 and Cp23 IgG levels increased with age till 24 months, after which levels started to decline ([Supplementary Figure 2](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw730/-/DC1)). Geometric mean IgG levels increased with an increasing number of previous infections ([Supplementary Figure 3](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw730/-/DC1)). There was no association between preexisting gp15 or Cp23 IgG levels and subsequent cryptosporidial infection ([Supplementary Table 3](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw730/-/DC1)) or diarrheal disease after adjusting for age and previous infections ([Supplementary Table 4](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw730/-/DC1)).

Distribution of *Cryptosporidium* Species in the Cohort {#s14}
-------------------------------------------------------

Species could be determined for 473 of 733 (64.5%) episodes of cryptosporidiosis detected by stool PCR (77% and 67% of cryptosporidial diarrheal and nondiarrheal stool, respectively). *Cryptosporidium hominis* predominated and was identified in 347 (73.3%) infections in which species could be identified, followed by *C. parvum* (81 \[17.1%\]) ([Table 4](#T4){ref-type="table"}). Other species were *C. meleagridis* (5.2%) and *C. felis* (1%). Mixed infection with both *C. parvum* and *C. hominis* was identified in 14 (2.9%) episodes and *C. andersoni and C. muris* in 1 episode (0.2%). Species could not be identified in 260 (35.5%) episodes, of which 199 (76.5%) episodes were asymptomatic. On the gels, untyped samples generally had weaker bands, which may indicate lower amounts of parasite in samples.

###### 

Frequency of Infections Caused by Different Species of *Cryptosporidium* in a Birth Cohort of Children (n = 410) Followed up to 3 Years of Age in Vellore, India

  Species Distribution              All Infections   Symptomatic Infection   Asymptomatic Infection
  --------------------------------- ---------------- ----------------------- ------------------------
  Total No. of episodes             733              199                     534
  No. of species determined         473              138                     335
  * C. hominis*                     347 (73.3)       99 (71.7)               248 (74.0)
  * C. parvum*                      81 (17.1)        20 (14.5)               61 (18.2)
  * C. meleagridis*                 25 (5.2)         6 (4.3)                 19 (5.6)
  * C. felis*                       5 (1)            1 (0.7)                 4 (1.2)
  * *Mixed infections                                                        
  *  C. hominis* and *C. parvum*    14 (2.9)         12 (8.7)                2 (0.6)
  *  C. andersoni* and *C. muris*   1 (0.2)          0 (0)                   1 (0.3)

Data are presented as No. (%).

To assess species-specific repeated infection and protection against subsequent infection, analysis was restricted to 161 children for whom complete species data were available for all infections. For protection against subsequent infection, we evaluated the risk of primary and subsequent infections with *C. hominis* or non*--C. hominis* species ([Table 5](#T5){ref-type="table"}). There was no decrease in the risk of overall or species-specific asymptomatic or symptomatic cryptosporidiosis in later infections, indicating a lack of species-specific protection.

###### 

Rate Ratio for Subsequent Infection to That With *Cryptosporidium hominis*, According to Species of Primary Infection

  Infection                                                                   *C. hominis* Primary Infection   Non--*C. hominis* Primary Infection   Rate Ratio (95% CI)   *P* Value
  --------------------------------------------------------------------------- -------------------------------- ------------------------------------- --------------------- -----------
  No. of children                                                             116                              45                                                          
  Follow-up, child-months                                                     546.5                            242.1                                                       
  Any cryptosporidial infection                                               12.6 (10.5--15.0)                12.4 (9.6--15.8)                      1.02 (.7--1.4)        .9
  Asymptomatic infection                                                      7.3 (5.7--9.4)                   9.1 (6.6--12.5)                       0.80 (.5--1.2)        .3
  Symptomatic infection                                                       5.3 (3.7--7.6)                   3.3 (1.6--7.2)                        1.6 (.7--3.5)         .2
  Moderate or severe symptomatic infection                                    2.2 (1.3--4.0)                   0.8 (.2--7.6)                         2.6 (.6--12.1)        .2
  Homotypic^a^ infection                                                      8.4 (6.5--10.8)                  NA                                                          
  Any infection in children with nonhomotypic^b^ primary infection            NA                               9.5 (7.0--12.9)                       0.88 (.6--1.3)        .5
  Homotypic symptomatic infection                                             3.5 (2.2--5.5)                   NA                                                          
  Any symptomatic infection in children with nonhomotypic primary infection   NA                               2.9 (1.3--7.2)                        1.2 (.5--3)           .7

Data are shown as percentage (95% CI) unless otherwise indicated.

Abbreviation: CI, confidence interval; NA, not applicable.

^a^Infection with the same species as the primary infection.

^b^Infection with a different species than the primary infection.

HLA Typing {#s15}
----------

There was no significant association of homozygous and heterozygous HLA class II alleles in children with only asymptomatic or at least 1 symptomatic cryptosporidial infection ([Supplementary Tables 5](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw730/-/DC1) and [6](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw730/-/DC1)).

DISCUSSION {#s16}
==========

This intensive birth cohort study in southern India revealed a high burden of cryptosporidiosis with 97% of children infected by 3 years of age. Both infection and cryptosporidial diarrhea clustered in some children, but limited testing of HLA class II alleles did not find an association with susceptibility or protection. In this cohort, protection conferred by prior infection was slow to develop, required multiple infections for partial protection, and was not associated with the presence of serum antibodies.

The incidence of 0.86 episodes per child-year is higher than reported from cohort studies in Peru (0.22 episodes per child-year) \[[@CIT0017]\] and Guinea-Bissau (0.33 episodes per child-year) \[[@CIT0018]\]. This is because of the inclusion of serology; based on PCR alone, incidence would have been 0.60 episodes per child-year. Among urban Brazilian children followed for 4 years, Israeli Bedouin children followed for 2 years, and an urban Bangladeshi cohort followed for 2 years, approximately 31%, 49%, and 77%, respectively, developed cryptosporidial infection \[[@CIT0019]\]. The high rates of infection in this study are likely due to intensive surveillance and use of sensitive diagnostic methods and complementation by serology, as reported for other enteric pathogens \[[@CIT0005], [@CIT0022]\]. A recent report building on the case-control analysis from the Global Enteric Multicenter Study (GEMS) study also demonstrated the importance of cryptosporidial infection, although the focus was on severe disease and mortality \[[@CIT0002]\]. Similar to this study, the GEMS reanalysis showed that cryptosporidial diarrhea was more common in toddlers ([Table 2](#T2){ref-type="table"}).

The majority (60%) of children had only asymptomatic cryptosporidial infections, similar to cohorts in Peru (67%) and Bangladesh (72%) \[[@CIT0017], [@CIT0023]\] and cross-sectional studies in Venezuela (86.3%) \[[@CIT0024]\] and Thailand (64.2%) \[[@CIT0025]\]. However, 2 longitudinal studies from Brazil \[[@CIT0019]\] and Guatemala \[[@CIT0026]\] reported 79% and 65% cryptosporidial diarrhea, respectively. The high proportion of asymptomatic infections may be due to the highly infectious nature of the parasite, with constant exposure resulting in subclinical infections, especially in endemic areas where transmission is through multiple routes \[[@CIT0013], [@CIT0027]\]. Only 24 (1.1%) episodes of persistent diarrhea were observed in this cohort, of which 2 episodes were associated with *Cryptosporidium*, differing from longitudinal studies from Brazil \[[@CIT0027]\] and Guinea-Bissau \[[@CIT0028]\], which reported greater persistent diarrhea in children, but are older studies.

During the 3-year follow up, 81% of children had \>1 episode of cryptosporidiosis. Although the majority of children (97%) were infected, some children were more at risk for repeated infections and disease, with children with symptomatic cryptosporidiosis tending to have a higher risk of diarrhea when reinfected. This suggests host susceptibility for cryptosporidiosis. Studies by Kirkpatrick in Bangladesh and Haiti reported associations with HLA class II DQB1\*0301 and class I B\*15 I \[[@CIT0029], [@CIT0030]\]. In our study there was no significant association of any class II allele with asymptomatic or symptomatic infection, in contrast to the study in Bangladesh in which the class II DQB1\*0301 allele was significantly associated with asymptomatic infection. The number of children who were HLA typed was small (41 asymptomatic and 33 symptomatic) but similar to those in Bangladesh (32 asymptomatic and 34 symptomatic). Impaired cell-mediated immunity may be another reason for susceptibility, since CD4 T cells have a crucial role in protection against and resolution of cryptosporidiosis \[[@CIT0031]\]. Previous analysis of data from this and another cohort in the same location that did not include serology or HLA typing showed that presence of older siblings (*P* = .002) and stunting at 6 months of age (*P* = .019) were important risk factors for childhood cryptosporidiosis \[[@CIT0016]\].

The majority of cryptosporidial infections were associated with *C. hominis* (73%). *Cryptosporidium hominis* has been identified as the most common (ranging from 79% to 88%) species in children from the same region \[[@CIT0009], [@CIT0032]\], India \[[@CIT0033]\], and elsewhere \[[@CIT0005]\]. The predominance of the anthroponotic *C. hominis* species may indicate the primary role of person-to-person transmission of infection in this community \[[@CIT0016]\]. We could not demonstrate species-specific protection in children with primary *C. hominis* infection, and this may reflect the diversity of *C. hominis*, with a need for subtyping to determine whether there is subtype-specific protection.

Our study found limited protection (69%) against subsequent infection after 4 prior infections, without significant protection against symptomatic cryptosporidiosis after adjustment for potential confounders, reflecting partial immunity developed over time. Studies on US healthy adult volunteers have demonstrated that prior exposure results in reduction in disease severity and intensity of infection but not rate and duration of illness, indicating that protection is not conferred by a single exposure. However, volunteers with preexisting serum antibodies required higher challenge doses to acquire subsequent infections compared with seronegative adults \[[@CIT0036], [@CIT0037]\].

Although geometric mean antibody levels increased with number of infections in this cohort ([Supplementary Figure 3](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw730/-/DC1)), indicating a serological response to cryptosporidial infections, preexisting antibodies did not demonstrate any association with protection from subsequent infection or diarrheal disease. This highlights that humoral immunity may not play a major role in protection against cryptosporidial infections and disease, and the role of cell-mediated immunity needs more detailed consideration.

This study provides important insights into the natural history of cryptosporidiosis in an endemic semiurban slum community in southern India. The fact that almost all children in the study acquired cryptosporidial infection by 3 years of age indicates a high rate of transmission in the community. Children with symptomatic infection tended to have a higher probability of repeated diarrhea, suggestive of genetic susceptibility. Further understanding of susceptibility to or protection from disease will require larger studies with more detailed analysis of genetic associations and cell-mediated immunity in conjunction with epidemiological findings.
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